Akari Therapeutics (AKTX) announced that it has filed two new provisional patent applications with the United States Patent and Trademark Office, USPTO. The first application includes claims protecting Akari’s novel immuno-oncology payload, PH1, and its spliceosome modulatory mechanism of action, which is expected to provide a therapeutic benefit by activating the host immune system in the fight against cancer. The second patent filing includes claims for a combination therapy of PH1 pipeline ADCs with other immuno-oncology drugs that alleviate checkpoint inhibition and have demonstrated synergy with immune checkpoint inhibitors in preclinical models. These new patent applications are part of a growing patent portfolio strategy designed to further extend Akari’s proprietary position with respect to the Company’s novel PH1 payload. These filings also build upon Akari’s recent provisional patent filing in late September covering the use of Akari’s ADC platform to target cancer by modulating alternative splicing drivers within cancer cells.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKTX:
- Akari Therapeutics Completes August 2025 Notes Offering
- Akari Therapeutics Reveals Promising Preclinical Data for PH1
- Innovative Cancer Treatment Approach Drives Buy Rating for Akari Therapeutics
- Akari Therapeutics announces preclinical data on PH1
- Akari Therapeutics Stock (AKTX) Rises after Filing Patent for Novel Cancer Therapy